Name: ML 786 dihydrochloride
Price: 638.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    IC50: 2.1, 2.5 and 4.2 nM for B-RafV600E, C-Raf and wild-type B-Raf, respectivelyML 786 is a potent Raf kinase inhibitor. As one component of MAPK signal transduction pathway, the Raf isoform B-Raf has a high rate of activating mutation in melanoma (50-70%) and other cancers including papillary thyroid, ovarian, and colorectal. Inhibition of mutant B-Raf signaling, via either direct inhibition of the enzyme or inhibition of MEK, which is the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth.In vitro: ML 786 and its analog had been found to inhibit a significant number of kinases and were inhibitors of wild-type B-Raf and C-Raf. Although ML 786 and its analog displayed significant receptor tyrosine kinase activity, it was likely that such additional activity would not significantly contribute to pERK inhibition in melanoma tumors with constituitively activated B-Raf [1]. In vivo: ML 786 and its analog were found to have activity in vivo, as demonstrated by the fact that both compounds strongly inhibited the in vivo Raf pathway following a 75 or 100 mg/kg oral dose [1]. Clinical trial: N/A
- Properties
  - Alternative Name
    
    (R,Z)-3-(2-aminopropan-2-yl)-N-(7-((7-hydroxy-5,6-dihydro-1,8-naphthyridin-4-yl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)-5-(trifluoromethyl)benzimidic acid dihydrochloride
    
    CAS Number
    
    1237536-18-3
    
    Molecular Formula
    
    C29H29F3N4O3·2HCl
    
    Molecular Weight
    
    611.48
    
    Appearance
    
    White solid
    
    Purity
    
    98.00%
    
    Solubility
    
    <61.15mg/ml in DMSO; <61.15mg/ml in H2O
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

ML 786 dihydrochloride

ML 786 dihydrochloride

Background

We Also Recommend

ABT

L002

SR 3576